Quantification of the Role of Teupol® 25P and Graminex® G96 Compared to Hexanic Extract of Serenoa repens in Patients Affected by Lower Urinary Tract Symptoms During Treatment with Silodosin.

Medicina (Kaunas) · 2025 · PMC12300964 · PMID 40731854

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

approached significancep = 0.08so close (0.05 < p ≤ 0.1)

IPSS scores at T3 approached significance ( p = 0.08).

also in 8,237 other papers

showed a trendno p-value reported

Although Xipag ® showed a trend toward an association with reduced symptom scores at T2 and T3, the effect became statistically significant only at T4 (β = −0.49, p = 0.04).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Quantification of the Role of Teupol&lt;sup&gt;®&lt;/sup&gt; 25P and Graminex&lt;sup&gt;®&lt;/sup&gt; G96 Compared to Hexanic Extract of &lt;i&gt;Serenoa repens&lt;/i&gt; in Patients Affected by Lower Urinary Tract Symptoms During Treatment with Silodosin.

The sentences

Quantification of the Role of Teupol<sup>®</sup> 25P and Graminex<sup>®</sup> G96 Compared to Hexanic Extract of <i>Serenoa repens</i> in Patients Affected by Lower Urinary Tract Symptoms During Treatment with Silodosin.